Osemitamab

DB18219InvestigationalProtein Based Therapies

Osemitamab: Overview.

Mechanism
Curator reviewed
Also known as
IMMUNOGLOBULIN G1, ANTI-(HUMAN CLAUDIN 18.2) (HUMAN-MUS MUSCULUS MONOCLONAL TST001 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL TST001 .KAPPA.-CHAIN, DIMER
Code names
TST-001

Resolves to

Compound
UNIIH14V1A2F4DCAS2460539-61-9
Targets
P56856CLDN18

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Osemitamab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In